Join
Live feed
·
PRReleasevia Quantisnow
Minerva Neurosciences Inc logo

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

ByQuantisnow·Wall Street's wire, on your screen.
NERV· Minerva Neurosciences Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NERV (Minerva Neurosciences Inc) and more on Quantisnow.